ArticleBMC cancer2010
Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming.Cancer biology & therapy · 2025Article
- Upregulation of HIF1-α via an NF-κB/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli.Neoplasia (New York, N.Y.) · 2020Article
- Ductal carcinoma in situ of breast: update 2019.Pathology · 2019Review
- Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ.Journal of the National Cancer Institute · 2019Article
- Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.Virchows Archiv : an international journal of pathology · 2018Article
- Cancer stem cells and early stage basal-like breast cancer.World journal of obstetrics and gynecology · 2016Article
- The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.BMC cancer · 2015Article
- Racial disparities in risk of second breast tumors after ductal carcinoma in situ.Breast cancer research and treatment · 2014Article
- Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers.Geburtshilfe und Frauenheilkunde · 2014Article
- Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features.Breast cancer research : BCR · 2014Article
- Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer.Oncogene · 2014Article
- Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features.International journal of breast cancer · 2014Article
- Breast cancer subtypes and previously established genetic risk factors: a bayesian approach.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Article
- Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.BMC cancer · 2013Article
- Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ.Clinics (Sao Paulo, Brazil) · 2013Article
- In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
- A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ.International journal of breast cancer · 2013Article
- Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.Journal of Cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroarray gene-profiling of invasive breast cancer has identified different subtypes including luminal A, luminal B, HER2-overexpressing and basal-like groups. Basal-like invasive breast cancer is associated with a worse prognosis. However, the prognosis of basal-like ductal carcinoma in situ (DCIS) is still unknown. Our aim was to study the prognosis of basal-like DCIS in a large population-based cohort.
methodsAll 458 women with a primary DCIS diagnosed between 1986 and 2004, in Uppland and Västmanland, Sweden were included. TMA blocks were constructed. To classify the DCIS tumors, we used immunohistochemical (IHC) markers (estrogen-, progesterone-, HER2, cytokeratin 5/6 and epidermal growth factor receptor) as a surrogate for the gene expression profiling. The association with prognosis was examined for basal-like DCIS and other subtypes using Kaplan-Meier survival analyses and Cox proportional hazards regression models.
resultsIHC data were complete for 392 women. Thirty-two were basal-like (8.2%), 351 were luminal or HER2-positive (89.5%) and 9 unclassified (2.3%). Seventy-six women had a local recurrence of which 34 were invasive. Another 3 women had general metastases as first event. Basal-like DCIS showed a higher risk of local recurrence and invasive recurrence 1.8 (Confidence interval (CI) 95%, 0.8-4.2) and 1.9 (0.7-5.1), respectively. However, the difference was not statistically significant. Also, no statistically significant increased risk was seen for triple-negative or high grade DCIS.
conclusionsBasal-like DCIS showed about a doubled, however not statistically significant risk for local recurrence and developing invasive cancer compared with the other molecular subtypes. Molecular subtyping was a better prognostic parameter than histopathological grade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.